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pneumoniaeMethods: Isolates of S. pneumoniae collected from six hospitals participating in the Taiwan
Surveillance of Antimicrobial Resistance (TSAR) program III (2002) e VI (2008) were enrolled
in this study. Bacterial susceptibilities were determined by minimum inhibitory concentration.
The clinical data of source patients were collected retrospectively.
Results: A total of 330 nonduplicate S. pneumoniae isolates were enrolled in this study.
Sputum was the most common specimen source, followed by pus. The mean age of the source
patients was 38 years among these 330 patients, and 247 had various infections caused by
S. pneumoniae. The overall in-hospital mortality rate was 6% and most (60%)of the mortality
occurred in patients older than 65 years. The mortality rates among the patients age 65 years
and older and those age 5 years and younger were 12.9% (9 of 70) and 2.4% (2 of 83), respec-
tively. The rates of nonsusceptibility to penicillin by the meningitis criteria (PNSP-M) were
69.0% in 2002, 81.0% in 2004, 73.7% in 2006, and 74.5% in 2008. Resistance to erythromycin
and trimethoprim/sulfamethoxazole remained high. Using multivariate analysis, patients with
PNSP isolates were more likely to have a history of antibiotic exposure within the previous 15
days compared with patients with penicillin-susceptible (PSSP) isolates (nonmeningitis criteria:
29.70% vs. 18.34%, p Z 0.0288; meningitis criteria: 25.30% vs. 9.88%, p Z 0.006). Shock at
presentation was the risk factor for in-hospital mortality.
Conclusion: Our study demonstrated that the rates of penicillin nonsusceptibility among
S. pneumoniae remained high in Taiwan during the study period. Previous antibiotic exposure
was the only risk factor for subsequent acquisition of penicillin- nonsusceptible S. pneumoniae
compared with penicillin-susceptible S. pneumoniae. Judicious antibiotic use is important to
control the spread of drug nonsusceptible S. pneumoniae.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Streptococcus pneumoniae is one of the most common path-
ogens causing community-acquired infections. The major
invasive pneumococcal diseases include pneumonia, bacter-
emia, and meningitis and can result in high mortality despite
antimicrobial therapy, ranging from 20% to 50%.1e4 Penicillin
used to be the most important antibiotic against invasive
pneumococcal diseases. However, resistance to penicillin has
been noted since 1967.5 Prior to 2008, the penicillin suscep-
tibility breakpoint for S. pneumoniae was 0.12 mg/mL.6 In
2008, Clinical and Laboratory Standards Institute (CLSI)
provided two different criteria for penicillin susceptibility.7
For meningitis (M) isolates, S. pneumoniae with penicillin
minimum inhibitory concentration (MIC)  0.12 mg/mL was
classified as penicillin nonsusceptible S. pneumoniae menin-
gitis (PNSP-M).Fornonmeningitis (NM) isolates, S.pneumoniae
with penicillin MIC  4 mg/mL was classified as penicillin
nonsusceptible S. pneumoniae nonmeningitis (PNSP-NM).
According to previous studies in other regions, the prevalence
of penicillin nonsusceptibility among S. pneumoniae increased
rapidly since the 1990s, regardless of using M or NM criteria.8,9
High prevalence of PNSP-M (>60%) was reported by
several studies conducted during the late 20th and early 21th
centuries in Taiwan.3,10,11 However, twomajor public health
events have occurred in Taiwan since those studies. First,
prescription of antibiotics for patients with acute upper
respiratory tract infection without clinical evidence of
bacterial infection has been restricted since 2001.12 Second,
vaccination of seven-valent pneumococcal conjugated
vaccine (PCV-7) for children with high risk for pneumococcal
infection was implemented in October 2005. Introduction of
PCV-7might reduce the antibiotic resistance in pneumococci
due to shifting of prevalent pneumococcal serotypes.9Whether the penicillin susceptibility of pneumococci in
Taiwan changed after these two major events remained
unclear. The current study was conducted to investigate the
secular trend of antibiotic susceptibility in S. pneumoniae
and to identify factors association with acquisition of
penicillin-nonsusceptible S. pneumoniae in Taiwan.
Patients and methods
Bacterial isolates
S. pneumoniae isolates were collected as part of the Taiwan
Surveillance of Antimicrobial Resistance (TSAR) program from
medical centers and regional hospitals throughout Taiwan.
The participating hospitals are located in the four geographic
regions (northern, central, southern, and eastern) of Taiwan.
TSAR has been conducted biennially since 1998 and data from
TSAR I (1998) and II (2000) have been reported.13,14 TSAR IIIe
VI (2002, 2004, 2006, 2008) isolates were collected between
July and September from the same 26 hospitals, except for
2006when isolates were from 25 hospitals. To obtain relevant
clinical data, only the bacterial isolates and their source
patients whose associated information could be obtained
were enrolled in the current study. The associated demo-
graphic, clinical, and laboratory data of source patients from
whom the bacteria were isolated were collected to investi-
gate the risk factors for acquiring PNSP-M or PNSP-NM and
mortality among patients with pneumococcal infections.
Antimicrobial susceptibility test
Antimicrobial susceptibilities to various antimicrobial
agents, including penicillin, chloramphenicol, ceftriaxone,
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floxacin, and tetracycline were determined by MIC using
the CLSI reference microbroth dilution method.15 For
penicillin and ceftriaxone, NM and M criteria were used.7
PNSP-NM referred to isolates with penicillin MIC  4 mg/
mL whereas PSSP-NM (penicillin-susceptible S. pneumoniae
nonmeningitis) referred to isolates with penicillin
MIC  2 mg/mL using the NM criteria. PNSP-M referred to
isolates with penicillin MIC  0.12 mg/mL whereas PSSP-M
isolates had penicillin MIC  0.06 mg/mL using the M
criteria. Isolates with ceftriaxone MIC  2 mg/mL and
1 mg/mL were considered ceftriaxone nonsusceptible and
susceptible, respectively, by the NM criteria. By the M
criteria, ceftriaxone nonsusceptible and susceptible S
pneumoniae referred to those with ceftriaxone MIC  1 mg/
mL and 0.5 mg/mL, respectively.7
Statistical analysis
Continuous variables were described as mean  standard
deviation (SD) and compared using the Student t test, or
described as the median as well as range and compared
with the Wilcoxon rank-sum test if their distributions were
not normal. Categorical variables were compared with
a chi-square test or Fisher exact test if the expected values
were less than 10. Risk factors for penicillin non-
susceptibility and all-cause in-hospital mortality were
identified using logistic regression models. Statistical
analyses were performed using SAS 9.1.3 (SAS Institute,
Cary, NC, USA). All tests were two-tailed and p < 0.05 was
considered statistically significant.
Results
A total of 331 pneumococcal isolates collected between
2002 and 2008 (corresponding to TSAR III-VI) and their
source patients from six hospitals, including three medical
centers and three regional hospitals, were enrolled in the
current study initially. One patient was excluded due to
missing data. Information on patient demographics and
clinical data is presented in Table 1. The mean age of the
330 patients from whom the isolates were obtained was 38
years. The male to female ratio was 217:96 (the sex of 17
patients was unknown). Sputum was the most common
specimen source, followed by pus/wound. The most
common underlying disease was cardiovascular disease.
Based on clinical data, 247 of the 330 patients were
determined to be infected and 70 were colonized (Table 1).
By NM criteria, the overall penicillin nonsusceptible rate
among the 330 studied isolates was 30.4% (Table 2). During
the study period, there was a transient decrease in PNSP-
NM in TSAR V (2006) isolates compared with isolates of
TSAR III, IV, and VI (p Z 0.031) (Fig. 1). The overall non-
susceptibility to ceftriaxone was 19.4% by the NM criteria.
Almost all (92%) of the study isolates were resistant to
erythromycin and 70% were nonsusceptible to trimetho-
prim/sulfamethoxazole. Levofloxacin showed good activity
(TSAR III: 100%; TSAR IV: 95.1%; TSAR V: 97.4; TSAR VI:
96.6%) against the tested isolates (Table 2).
By M criteria, the overall penicillin nonsusceptibility was
75.7%. The proportion of PNSP-M was also lower in isolatesof TSAR V compared with isolates of TSAR III, IV, and VI, but
the difference was not statistically significant (pZ 0.549).
Sixty-three percent of the 330 pneumococci isolates were
nonsusceptible to ceftriaxone by the M criteria (Table 2).
Patients with PNSP-NM or PNSP-M isolates were more
likely to have a history of antibiotic exposure within the
previous 15 days compared with patients with PSSP by
either NM or M criteria (NM: 29.70% vs. 18.34%, pZ 0.0288;
M: 25.30% vs. 9.88%, p Z 0.006). Using univariate and
multivariate analysis by logistic regression models, previous
antibiotic exposure was an independent risk factor for
acquiring PNSP-NM or PNSP-M isolates (PNSP-NM, odds ratio
[OR]: 2.848, 95% confidence interval [CI]: 1.374-5.901,
p Z 0.0049; PNSP-M, OR-3.730, 95% CI: 1.644-8.459,
pZ 0.002) (Table 3). No specific antibiotic used previously
could be identified to be associated with acquiring PNSP.
Among the 247 pneumococci-infected patients, the
mean age was 36 years and lower respiratory tract infection
was the most common foci (144 of 247). PNSP-NM accoun-
ted for 32% (79 of 247) of all invasive pneumococcal
infections and the overall in-hospital mortality was 6% (15
of 247). Sixty percent of the mortality cases (9 of 15)
occurred in patients older than 65 years. The mortality
rates among the patients older than 65 years and those
younger than 5 years were 12.9% (9 of 70) and 2.4% (2 of
83), respectively. There was no difference in mortality
between PSSP-NM and PNSP-NM infected patients or
between PSSP-M and PNSP-M infected patients (PSSP-NM vs.
PNSP-NM: 5.88% vs. 8.00%, pZ 0.5755; PSSP-M vs. PNSP-M:
6.55% vs. 6.45%, p Z 1.000). There was also no difference
in mortality between patients with infection caused by
ceftriaxone susceptible and nonsusceptible strains either
by NM or M criteria (NM criteria: 5.91% vs. 9.09%,
pZ 0.4960; M criteria: 7.77% vs. 5.73%, pZ 0.5950). Shock
at presentation was the only risk factor for in-hospital
mortality for patients with infection caused by S pneumo-
niae either by univariate or multivariate analysis (OR: 40.1,
95% CI: 7.5 - 213.4, p < 0.0001).Discussion
The emergence and rapid dissemination of antibiotic-
resistant pneumococcal strains has been noted since the
1990s, and was found to be associated with previous anti-
biotic consumption.16,17 Our study of pneumococcal
isolates from six hospitals showed that the rates of peni-
cillin nonsusceptibility in S. pneumoniae in Taiwan, either
by M or NM criteria, remained high in Taiwan. However,
there was a transient decrease in penicillin non-
susceptibility in TSAR V (2006), especially by NM criteria
(p Z 0.031).
Transient decreased penicillin nonsusceptibility in
pneumococci was also noted in the SENTRY Antimicrobial
Surveillance Program,9 and in a surveillance system in
Spain (Spanish Reference Laboratory for Pneumococci,
SRLP).18 In the SENTRY program, it was found that the
rates of b-lactam nonsusceptibility in pneumococci
increased during 1998-2001 but later decreased during
2002-2003, and then increased again during 2004 and 2009.
In that surveillance, penicillin and ceftriaxone non-
susceptibility of pneumococci (by NM criteria) in 2008 was
Table 1 Comparison of demographics and clinical characteristics of 330 patients with carriage or infection by S. pneumoniae
stratified by penicillin susceptibility










TSAR (yr), n (%)
Ⅲ (2002) 41 (17.90) 18 (18.00) 0.0081 18 (22.20) 40 (16.06) 0.3620
IV (2004) 63 (27.51) 41 (41.00) 20 (24.69) 85 (34.13)
V (2006) 64 (27.95) 12 (12.00) 20 (24.69) 56 (22.48)
VI (2008) 61 (26.64) 29 (29.00) 23 (28.40) 67 (26.90)
Age, mean  SD (y) 38.27  30.68 39.00  32.59 0.2527 43.10  29.46 36.98  31.71 0.0760
Male to female 152/67 65/29 0.9630 48/29 168/67 0.1150
Isolated specimen site, n (%)
Blood 16 (6.98) 14 (13.86) 0.2741 9 (11.11) 22 (8.84) 0.8770
Sputum 123 (53.71) 56 (55.45) 43 (53.09) 135 (54.21)
Urine 1 (0.44) 0 (0.00) 0 (0.00) 1 (0.40)
Pus/wound 47 (20.52) 20 (19.80) 15 (18.52) 52 (20.88)
Others 24 (10.48) 9 (8.91) 9 (11.11) 24 (9.62)
Throat swab 12 (5.24) 1 (0.99) 4 (4.93) 9 (3.61)
Nasal swab 3 (1.31) 1 (0.99) 0 (0.00) 4 (1.61)
Underlying condition, n (%)
DM 30 (13.10) 14 (13.86) 0.7601 8 (9.88) 36 (14.46) 0.1950
Renal dx 7 (3.06) 2 (1.98) 0.7290 1 (1.23) 8 (3.21) 0.4520
CAD 45 (19.65) 23 (22.77) 0.4129 17 (20.99) 51 (20.48) 0.8740
GI dx 12 (5.24) 8 (7.92) 0.3047 3 (3.70) 17 (6.82) 0.2970
Cancer 15 (6.55) 8 (7.92) 0.5920 3 (3.70) 20 (8.03) 0.1450
Immunosuppression 5 (2.18) 6 (5.94) 0.0912 2 (2.47) 9 (3.61) 0.7330
Neutropenia 1 (0.43) 0 (0.00) 1.0000 0 (0.00) 1 (0.40) 1.0000
Other 39 (17.03) 13 (12.87) 0.3916 14 (17.28) 38 (15.26) 1.0000
Respiratory dx 30 (13.10) 20 (19.80) 0.0837 16 (19.75) 34 (13.65) 0.3720
Neurologic dx 23 (10.04) 16 (15.84) 0.1006 9 (11.11) 30 (12.05) 0.6970
Hepatic dx 13 (5.68) 8 (7.92) 0.3924 4 (4.94) 17 (6.83) 0.4590
Autoimmune dx 3 (1.31) 0 (0.00) 0.5567 1 (1.23) 2 (0.80) 1.0000
Living in LTCF or RCW
within recent 1 y, n (%)
14 (6.11) 12 (11.88) 0.0778 6 (7.40) 20 (8.03) 1.0000
Hospitalization within
recent 1 y, n (%)
90 (39.30) 50 (49.50) 0.0986 28 (34.57) 111 (44.57) 0.1220
Invasive therapy
(H/D, C/T) within
recent 1 y, n (%)
10 (4.37) 1 (1.00) 0.1829 0 (0.00) 11 (4.44) 0.0720
Antibiotic use within
prior 15 days, n (%)
42 (18.34) 30 (29.70) 0.0288 8 (9.88) 63 (25.30) 0.0060
Infection or colonization, n (%)
Colonization 51 (22.27) 19 (18.81) 0.4392 16 (19.75) 54 (21.69) 0.7570
Infection 168 (73.36) 79 (78.21) 61 (75.30) 186 (74.70)
Mortality, n (%) 15 (6.98) 6 (5.94) 1.000 6 (7.41) 15 (6.02) 0.7930
CAD Z coronary artery disease; C/T Z chemotherapy; DM Z diabetic mellitus; dx Z disease; GI Z gastrointestinal;
H/D Z hemodialysis; LTCF Z long-term care facility; M Z meningitis; NM Z nonmeningitis; RCW Z respiratory care ward;
PNSP-M Z penicillin-nonsusceptible S. pneumoniae meningitis; PNSP-NM Z penicillin-nonsusceptible S. pneumoniae nonmeningitis;
PSSP-M Z penicillin-susceptible S. pneumoniae meningitis; PSSP-NM Z penicillin-susceptible S. pneumoniae nonmeningitis;
SD Z standard deviation; TSAR Z Taiwan Surveillance of Antimicrobial Resistance.
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30.4% and 19.4%, respectively. In SRLP, the prevalence of
PNSP-M decreased in the past decade, especially during
2005e2008.18 The decrease of penicillin nonsusceptibility
rate in both programs was proposed to be associated withthe introduction of pneumococcal vaccine, which resulted
in clonal shifts from multidrug-resistant (MDR) clones to
non-MDR clones not covered by the vaccine.19 Studies on
resistance in different serotypes in Taiwan have also
shown that serotypes in PCV-7 vaccine have higher rates of
Table 2 Antibiotic susceptibilities of S. pneumoniae in different years
TSAR (y) % of isolates susceptible
PEN-NM PEN-M CRO-NM CRO-M ERY TMP/SMX LVX CHL TCY
TSAR-III (2002) 69.5 31.0 78.1 44.1 10.2 37.2 100 49.2 3.3
TSAR-IV (2004) 60.5 19.0 85.6 32.7 9.4 23 95.1 55.1 6.7
TSAR-V (2006) 84.2 26.3 90.7 43.4 10.5 26.3 97.4 60.6 5.3
TSAR-VI (2008) 67.7 25.5 78.9 32.2 5.6 33.3 96.6 41.7 4.4
Overall 69.6 24.3 80.6 37.1 7.9 29.2 97 55.7 5.2
CHLZ chloramphenicol; CRO-MZ ceftriaxone by meningitis criteria (susceptible, minimum inhibitory concentration [MIC]  0.5 ug/mL;
nonsusceptible, MIC  1 ug/mL); CRO-NM Z ceftriaxone by nonmeningitis criteria (susceptible, MIC  1 ug/mL; nonsusceptible,
MIC  2 ug/mL); ERY Z erythromycin; LVX Z levofloxacin; PEN-M Z penicillin by meningitis criteria (susceptible, MIC  0.06 ug/mL;
nonsusceptible, MIC  0.12 ug/mL); PEN-NM Z penicillin by nonmeningitis criteria (susceptible, MIC  2 ug/mL; nonsusceptible,
MIC  4 ug/mL); TCY Z tetracycline; TMP/SMX Z trimethoprim/sulfamethoxazole; TSAR Z Taiwan Surveillance of Antimicrobial
Resistance.
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decrease of penicillin nonsusceptibility in S. pneumoniae
isolates collected in TSAR V (2006) might be related to the
introduction of PCV-7 in Taiwan in 2005.
Our study also found that the proportion of PNSP-M was
also lower in isolates of TSAR V compared with those of
TSAR III, IV, and IV, but the difference was not statistically
significant (pZ 0.549). Fig. 2 demonstrates the cumulative
distribution of MICs to penicillin of tested isolates. For the
proportion of isolates with penicillin MIC  1 mg/mL, that of
isolates from TSAR V was only slightly higher than those
from TSAR III, IV, and VI. However, for the proportion of
isolates with a penicillin MIC of 2 mg/mL, that of isolates
from TSAR V was much higher than those from TSAR III, IV,
and VI. This is why there was a statistically significant
decrease in PNSP-NM in TSAR V, but only a slight decrease
(without statistical significance) in PNSP-M.
Decreased antibiotic usage resulting from restriction of
antibiotics among patients in Taiwan with acute upper
respiratory tract infection without clinical evidence of
bacterial infection since 2001 has been reported.22
However, we did not find any decrease in rates of non-
susceptibility to erythromycin, tetracycline, and trimetho-
prim/sulfamethoxazole, three of the commonly used first-
line antibiotics in Taiwan outpatients, in pneumococci in
Taiwan. One reason for this is that pneumococci in Taiwan
are mostly MDR.10,11,14 Thus, the use of one of theFigure 1. Trends of penicillin and ceftriaxone susceptibility
in Taiwan Surveillance of Antimicrobial Resistance (TSAR)
periods.antimicrobial agents would select for the MDR strains. The
rates of erythromycin (92%)and trimethoprim/sulfame-
thoxazole (70%) nonsusceptibility in pneumococci in Taiwan
remained much higher than isolates from the United States
where nonsusceptibility to these two agents was 37% and
33%, respectively.9 Therefore, treatment choices are more
limited for pneumococcal infections in Taiwan. Although
resistance of pneumococci to levofloxacin did not increase
significantly and remained at less than 5% overall during the
study period, a finding similar to those from other coun-
tries,9,18,23 judicious use of this class of antibiotics is
warranted.
Our study found that previous antibiotic exposure within
15 days before isolation of pneumococci was the only
independent factor associated with penicillin non-
susceptibility using either N or NM criteria. Previous anti-
biotics exposure would facilitate the subsequent
acquisition of drug-resistant bacteria due to selection
pressure.24,25 It was therefore reasonable that we found
previous antibiotic use to be associated with PNSP-M or
PNSP-NM carriage/infection in the current study. Although
previous studies from other countries have reported similar
findings,24,26e28 this is the first report demonstrating the
association of antibiotic use and penicillin-nonsusceptible
pneumococci in Taiwan.
Compared with PSSP-M, infection caused by PNSP-M has
been associated with higher mortality in some studies,1,29
but some studies found no association between penicillin-
nonsusceptibility and poorer patient outcome.30,31 In the
current study we found no significant difference in the
mortality of patients infected by PSSP-M and PNSP-M or
between PSSP-NM and PNSP-NM isolates but shock at
presentation was significantly associated with in-hospital
mortality in infected patients. The overall in-hospital
mortality rate of pneumococcal disease in our study was
6%, a rate lower than those reported in previous studies,
which ranged from 14% to 23%.31e33 The mortality rates
among the patients age 65 years and older and age 5 years
and younger (12.9% and 2.4%, respectively) were also lower
than previous reports.34,35 Our study encompassed isolates
from different sources and the proportion of patients with
invasive pneumococcal disease was less than previous
studies, which likely contributed to the lower mortality
rate found in the current study. However, we did find 60% of
Table 3 Factors significantly associated with carriage or infection by PNSP-M or PNSP-NM; results by univariate analysis
Parameters Nonmeningitis criteria Meningitis criteria
Odds ratio 95% CI p Odds ratio 95% CI p
TSAR III (2002)
TSAR IV (2004) 1.404 0.718 2.748 0.3214 1.912 0.913 4.006 0.086
TSAR V (2006) 0.405 0.178 0.921 0.0310 1.260 0.592 2.681 0.549
TSAR VI (2008) 1.026 0.509 2.068 0.9430 1.311 0.631 2.722 0.468
Antibiotic use within prior 15 days 1.852 1.062 3.2320 0.0299 3.088 1.396 6.831 0.005
TSAR Z Taiwan Surveillance of Antimicrobial Resistance; PNSP-M Z penicillin-nonsusceptible S. pneumoniae meningitis; PNSP-
NM Z penicillin-nonsusceptible S. pneumoniae nonmeningitis.
Figure 2. Cumulative distribution of minimum inhibitory
concentrations (MICs) of S. pneumoniae to penicillin from
Taiwan Surveillance of Antimicrobial Resistance (TSAR) III to
TSAR VI.
350 H.-Y. Tsai et al.the mortality cases in our study occurred in patients age 65
years and older, which is compatible to the previous finding
that older age ( 65 years) is significantly associated with
case-fatality of invasive pneumococcal disease.34
In conclusion, we found that penicillin nonsusceptibility
of S. pneumoniae in Taiwan remained high, albeit a tran-
sient decrease was noted during the study period. Although
we did not find significant difference in mortality in
patients infected with penicillin-nonsusceptible and
-susceptible isolates, we did show that previous antibiotic
exposure was an independent factor associated with
subsequent acquisition of penicillin-nonsusceptible pneu-
mococci. Therefore, judicious antibiotic use is an important
measure to control the spread of penicillin-nonsusceptible
pneumococci. Continued surveillance is needed to
monitor changes in pneumococcal resistance as vaccination
programs change in Taiwan.References
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